Clinical Trials
166 trialsStudy of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
Acerta Pharma BV
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
BeOne Medicines
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
BeOne Medicines
BELLWAVE-011
Merck Sharp & Dohme LLC
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
BeOne Medicines
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
National Cancer Institute (NCI)
MAJIC
AstraZeneca
BELLWAVE-010
Merck Sharp & Dohme LLC
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Newave Pharmaceutical Inc
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie
SIGMA
Grifols Biologicals, LLC
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Acerta Pharma BV
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
BeOne Medicines
CaDAnCe-302
BeOne Medicines
CaDAnCe-303
BeOne Medicines
CAN3001
Janssen Research & Development, LLC
GLOW
Janssen Research & Development, LLC
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
BRUIN CLL-321
Eli Lilly and Company
BRUIN-CLL-314
Eli Lilly and Company
EXCELL
Grifols Therapeutics LLC
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
AbbVie
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Nurix Therapeutics, Inc.
Auto-LLC 2001
University Hospital, Caen
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Dizal Pharmaceuticals
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
Merck Sharp & Dohme LLC
SEQUOIA
BeOne Medicines
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
AstraZeneca
CRISTALLO
Hoffmann-La Roche
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Dartmouth-Hitchcock Medical Center
BRUIN CLL-322
Eli Lilly and Company
BRUIN CLL-313
Eli Lilly and Company
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Alliance for Clinical Trials in Oncology
ASSURE
AstraZeneca
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
Hoffmann-La Roche
Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)
Octapharma
BOOST-IC
Monash University
ElevateTN
Acerta Pharma BV
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
German CLL Study Group
SEVENAZA
Gustave Roussy, Cancer Campus, Grand Paris
ALPINE
BeiGene
FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia
German CLL Study Group
CLL12
German CLL Study Group
GAIA
German CLL Study Group
AMPLIFY
Acerta Pharma BV
UNITY-CLL
TG Therapeutics, Inc.